{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:08:07Z","timestamp":1793210887921,"version":"4.5.0"},"reference-count":228,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (Youth Foundation)","doi-asserted-by":"publisher","award":["82204864"],"award-info":[{"award-number":["82204864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (Youth Foundation)","doi-asserted-by":"publisher","award":["82030117"],"award-info":[{"award-number":["82030117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (Key Program)","doi-asserted-by":"publisher","award":["82204864"],"award-info":[{"award-number":["82204864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (Key Program)","doi-asserted-by":"publisher","award":["82030117"],"award-info":[{"award-number":["82030117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Histone deacetylase 3 (HDAC3) has emerged as a critical epigenetic regulator in tumor progression and immune modulation, positioning it as a promising target for enhancing cancer immunotherapy. This work comprehensively explores HDAC3\u2019s multifaceted roles, focusing on its regulation of key immune-modulatory pathways such as cGAS-STING, ferroptosis, and the Nrf2\/HO-1 axis. These pathways are central to tumor immune evasion, antigen presentation, and immune cell activation. Additionally, the distinct effects of HDAC3 on various immune cell types\u2014including its role in enhancing T cell activation, restoring NK cell cytotoxicity, promoting dendritic cell maturation, and modulating macrophage polarization\u2014are thoroughly examined. These findings underscore HDAC3\u2019s capacity to reshape the tumor immune microenvironment, converting immunologically \u201ccold tumors\u201d into \u201chot tumors\u201d and thereby increasing their responsiveness to immunotherapy. The therapeutic potential of HDAC3 inhibitors is highlighted, both as standalone agents and in combination with immune checkpoint inhibitors, to overcome resistance and improve treatment efficacy. Innovative strategies, such as the development of selective HDAC3 inhibitors, advanced nano-delivery systems, and integration with photodynamic or photothermal therapies, are proposed to enhance treatment precision and minimize toxicity. By addressing challenges such as toxicity, patient heterogeneity, and resistance mechanisms, this study provides a forward-looking perspective on the clinical application of HDAC3 inhibitors. It highlights its significant potential in personalized cancer immunotherapy, paving the way for more effective treatments and improved outcomes for cancer patients.<\/jats:p>","DOI":"10.3390\/vaccines13020182","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:05:42Z","timestamp":1739437542000},"page":"182","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["HDAC3: A Multifaceted Modulator in Immunotherapy Sensitization"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8856-3681","authenticated-orcid":false,"given":"Rui","family":"Han","sequence":"first","affiliation":[{"name":"Oncology Department of Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China"},{"name":"Department of Chinese Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Luo","sequence":"additional","affiliation":[{"name":"Oncology Department of Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China"},{"name":"Department of Chinese Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Gao","sequence":"additional","affiliation":[{"name":"Oncology Department of Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China"},{"name":"Department of Chinese Medicine, Naval Medical University, Shanghai 200433, China"},{"name":"Oncology Department, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine Suzhou, Suzhou 215009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Zhou","sequence":"additional","affiliation":[{"name":"Oncology Department of Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China"},{"name":"Department of Chinese Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian","family":"Wang","sequence":"additional","affiliation":[{"name":"Oncology Department of Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China"},{"name":"Department of Chinese Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Oncology Department of Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China"},{"name":"Department of Chinese Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6704-1569","authenticated-orcid":false,"given":"Guoyin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Oncology Department of Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China"},{"name":"Department of Chinese Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changquan","family":"Ling","sequence":"additional","affiliation":[{"name":"Oncology Department of Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China"},{"name":"Department of Chinese Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/jbmr\/zjae085","article-title":"Hdac3-deficiency increases senescence-associated distention of satellite DNA and telomere-associated foci in osteoprogenitor cells","volume":"39","author":"Yeo","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41420-024-02115-y","article-title":"HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks","volume":"10","author":"Cassandri","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1541-7786.MCR-20-0214","article-title":"HDAC3 Is Required for XPC Recruitment and Nucleotide Excision Repair of DNA Damage Induced by UV Irradiation","volume":"18","author":"Nishimoto","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC Inhibitors in Cancer Development and Therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Aleksandrova, Y., Munkuev, A., Mozhaitsev, E., Suslov, E., Tsypyshev, D., Chaprov, K., Begunov, R., Volcho, K., Salakhutdinov, N., and Neganova, M. (2023). Elaboration of the Effective Multi-Target Therapeutic Platform for the Treatment of Alzheimer\u2019s Disease Based on Novel Monoterpene-Derived Hydroxamic Acids. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119743"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: Emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e13731","DOI":"10.1111\/cpr.13731","article-title":"HDAC3 in action: Expanding roles in inflammation and inflammatory diseases","volume":"58","author":"He","year":"2024","journal-title":"Cell Prolif."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Paluvai, H., Shanmukha, K.D., Tyedmers, J., and Backs, J. (2023). Insights into the function of HDAC3 and NCoR1\/NCoR2 co-repressor complex in metabolic diseases. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1190094"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"116129","DOI":"10.1016\/j.ejmech.2024.116129","article-title":"HDAC-targeting epigenetic modulators for cancer immunotherapy","volume":"265","author":"Cheng","year":"2024","journal-title":"Eur. J. Med. Chem. Chim. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.omto.2020.08.017","article-title":"Valeric acid suppresses liver cancer development by acting as a novel HDAC inhibitor","volume":"19","author":"Han","year":"2020","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12032-022-01814-9","article-title":"Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer","volume":"39","author":"Han","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/sj.onc.1210612","article-title":"HDAC3: Taking the SMRT-N-CoRrect road to repression","volume":"26","author":"Karagianni","year":"2007","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kwon, Y., Kim, Y., Jung, H.S., and Jeoung, D. (2018). Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010051"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00109-021-02141-8","article-title":"Histone deacetylase 3 (HDAC3) as an important epigenetic regulator of kidney diseases","volume":"100","author":"Zhang","year":"2022","journal-title":"J. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s43018-022-00375-0","article-title":"Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity","volume":"3","author":"Tsai","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.chembiol.2023.07.010","article-title":"HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation","volume":"30","author":"Xiao","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/15548627.2015.1017192","article-title":"The role of STAT3 in autophagy","volume":"11","author":"You","year":"2015","journal-title":"Autophagy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020034380","article-title":"The Relationship between HDAC3 and Malignant Tumors: A Mini Review","volume":"30","author":"Tong","year":"2020","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.nlm.2011.04.005","article-title":"HDAC3 and the molecular brake pad hypothesis","volume":"96","author":"McQuown","year":"2011","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1101\/sqb.2011.76.011494","article-title":"Circadian epigenomic remodeling and hepatic lipogenesis: Lessons from HDAC3","volume":"76","author":"Sun","year":"2011","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.14336\/AD.2021.1116","article-title":"Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis","volume":"13","author":"Jiang","year":"2022","journal-title":"Aging Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41580-018-0076-0","article-title":"Integrative regulation of physiology by histone deacetylase 3","volume":"20","author":"Emmett","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/cac2.12180","article-title":"KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression","volume":"41","author":"Wei","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41418-023-01139-8","article-title":"Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RAR\u03b1","volume":"30","author":"Dai","year":"2023","journal-title":"Cell Death Differ."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","article-title":"NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance","volume":"631","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"eadd3243","DOI":"10.1126\/sciadv.add3243","article-title":"HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non-small cell lung cancer","volume":"9","author":"Eichner","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Palamaris, K., Tzimou, L.M., Levidou, G., Masaoutis, C., Theochari, I., Rontogianni, D., and Theocharis, S. (2023). Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054263"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.canlet.2021.09.001","article-title":"Vorinostat triggers miR-769-5p\/3p-mediated suppression of proliferation and induces apoptosis via the STAT3-IGF1R-HDAC3 complex in human gastric cancer","volume":"521","author":"Dai","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13148-024-01700-3","article-title":"Anti-tumour activity of Panobinostat in oesophageal adenocarcinoma and squamous cell carcinoma cell lines","volume":"16","author":"Lopes","year":"2024","journal-title":"Clin. Epigenet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.yjmcc.2010.11.009","article-title":"Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart","volume":"51","author":"McKinsey","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mayer, M., Berger, A., Leischner, C., Renner, O., Burkard, M., B\u00f6cker, A., Noor, S., Weiland, T., Weiss, T.S., and Busch, C. (2022). Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma. Pharmaceuticals, 15.","DOI":"10.3390\/ph15040438"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/DDDT.S234871","article-title":"RGFP966 Suppresses Tumor Growth and Migration Through Inhibition of EGFR Expression in Hepatocellular Carcinoma Cells in vitro","volume":"14","author":"Yu","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1158\/1535-7163.MCT-20-0037","article-title":"A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1\/IL6\/STAT3 Signaling Axis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","article-title":"Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma","volume":"10","author":"Mondello","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.pan.2019.01.011","article-title":"HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer","volume":"19","author":"Hu","year":"2019","journal-title":"Pancreatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.18632\/oncotarget.2154","article-title":"Histone deacetylase inhibitor treatment induces \u2018BRCAness\u2019 and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells","volume":"5","author":"Ha","year":"2014","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s13402-019-00439-x","article-title":"Endocrine resistant breast cancer cells with loss of ER\u03b1 expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage","volume":"43","author":"Yu","year":"2020","journal-title":"Cell Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., and Zhou, H. (2022). Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells, 11.","DOI":"10.3390\/cells11030320"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.ccell.2023.08.014","article-title":"Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I","volume":"41","author":"Ferrari","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1038\/s41467-023-39920-5","article-title":"ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"83155","DOI":"10.18632\/oncotarget.17950","article-title":"HDAC inhibitors enhance the immunotherapy response of melanoma cells","volume":"8","author":"Booth","year":"2017","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e2317694121","DOI":"10.1073\/pnas.2317694121","article-title":"Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors","volume":"121","author":"McGuire","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"112171","DOI":"10.1016\/j.ejmech.2020.112171","article-title":"Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review","volume":"192","author":"Sarkar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Suresh, P.S., Devaraj, V.C., Srinivas, N.R., and Mullangi, R. (2017). Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine. Biomed. Chromatogr., 31.","DOI":"10.1002\/bmc.3807"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":"Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.2174\/0929867327666200203113926","article-title":"Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy","volume":"28","author":"Pojani","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2217\/fon.15.62","article-title":"Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"11","author":"Rashidi","year":"2015","journal-title":"Future Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/1078-0432.CCR-18-1153","article-title":"Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma","volume":"25","author":"Desmots","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ejmech.2018.10.072","article-title":"Therapeutic potential of selective histone deacetylase 3 inhibition","volume":"162","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12033","DOI":"10.1021\/acs.jmedchem.3c00614","article-title":"Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer","volume":"66","author":"Pulya","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Cao, F., Zwinderman, M.R.H., and Dekker, F.J. (2018). The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors. Molecules, 23.","DOI":"10.3390\/molecules23030551"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1158\/1078-0432.CCR-16-2271","article-title":"Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer","volume":"23","author":"Tanimoto","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1007\/s11064-016-2043-5","article-title":"Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-\u03baB-Dependent Transcription in Glioblastoma Cell Lines","volume":"41","author":"Li","year":"2016","journal-title":"Neurochem. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"114470","DOI":"10.1016\/j.ejmech.2022.114470","article-title":"Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer","volume":"238","author":"Pulya","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/pros.23467","article-title":"Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer","volume":"78","author":"McLeod","year":"2018","journal-title":"Prostate"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","article-title":"HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"101779","DOI":"10.1016\/j.tranon.2023.101779","article-title":"Defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome na\u00efve resistance to pan-HDACi in diffuse large B cell lymphoma","volume":"39","author":"Havas","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4048\/jbc.2014.17.4.323","article-title":"Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast","volume":"17","author":"Seo","year":"2014","journal-title":"J. Breast Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/j.wneu.2018.07.076","article-title":"HDAC3 Expression Correlates with the Prognosis and Grade of Patients with Glioma: A Diversification Analysis Based on Transcriptome and Clinical Evidence","volume":"119","author":"Zhong","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.18632\/aging.204071","article-title":"Comprehensive analysis of histone deacetylases genes in the prognosis and immune infiltration of glioma patients","volume":"14","author":"Shen","year":"2022","journal-title":"Aging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"305","DOI":"10.17219\/acem\/66207","article-title":"Deregulated expression of HDAC3 in colorectal cancer and its clinical significance","volume":"27","author":"Nemati","year":"2018","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/CAD.0000000000000610","article-title":"Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma","volume":"29","author":"Huang","year":"2018","journal-title":"Anticancer Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.12659\/MSM.906576","article-title":"Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer","volume":"24","author":"Cui","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"16505","DOI":"10.18632\/oncotarget.7663","article-title":"Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer","volume":"7","author":"Jiao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Lv, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., and Wang, C. (2022). Immunotherapy: Reshape the Tumor Immune Microenvironment. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.844142"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41419-020-02968-y","article-title":"Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"65","DOI":"10.21037\/tcr-23-1228","article-title":"A pancancer analysis of histone deacetylase 3 in human tumors","volume":"13","author":"Chen","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ghiboub, M., Zhao, J., Li Yim, A.Y.F., Schilderink, R., Verseijden, C., van Hamersveld, P.H.P., Duarte, J.M., Hakvoort, T.B.M., Admiraal, I., and Harker, N.R. (2020). HDAC3 Mediates the Inflammatory Response and LPS Tolerance in Human Monocytes and Macrophages. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.550769"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.immuni.2018.12.018","article-title":"The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages","volume":"50","author":"Schulthess","year":"2019","journal-title":"Immunity"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13148-022-01336-1","article-title":"PDCD5 inhibits progression of renal cell carcinoma by promoting T cell immunity: With the involvement of the HDAC3\/microRNA-195-5p\/SGK1","volume":"14","author":"Liu","year":"2022","journal-title":"Clin. Epigenet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/JLB.1RI0418-168R","article-title":"NCOR1-a new player on the field of T cell development","volume":"104","author":"Hainberger","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Zhang, F., Shi, Y., Wang, L., and Sriram, S. (2011). Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016795"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS-STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s10020-023-00769-5","article-title":"ALDH2 mitigates LPS-induced cardiac dysfunction, inflammation, and apoptosis through the cGAS\/STING pathway","volume":"29","author":"Liu","year":"2023","journal-title":"Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e70283","DOI":"10.1002\/cam4.70283","article-title":"Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR-T-Cell Therapy","volume":"13","author":"Zhang","year":"2024","journal-title":"Cancer Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41419-024-06685-8","article-title":"Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"111991","DOI":"10.1016\/j.celrep.2023.111991","article-title":"Glycosyltransferase Extl1 promotes CCR7-mediated dendritic cell migration to restrain infection and autoimmunity","volume":"42","author":"Liu","year":"2023","journal-title":"Cell Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.immuni.2019.01.021","article-title":"CCR7 Chemokine Receptor-Inducible lnc-Dpf3 Restrains Dendritic Cell Migration by Inhibiting HIF-1\u03b1-Mediated Glycolysis","volume":"50","author":"Liu","year":"2019","journal-title":"Immunity"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Brandum, E.P., J\u00f8rgensen, A.S., Rosenkilde, M.M., and Hjort\u00f8, G.M. (2021). Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158340"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","article-title":"Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy","volume":"30","author":"Lv","year":"2020","journal-title":"Cell Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"eadi2465","DOI":"10.1126\/sciadv.adi2465","article-title":"Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation","volume":"9","author":"Xiang","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9644","DOI":"10.7150\/thno.47651","article-title":"HDAC3 inhibition ameliorates ischemia\/reperfusion-induced brain injury by regulating the microglial cGAS-STING pathway","volume":"10","author":"Liao","year":"2020","journal-title":"Theranostics"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2023.08.012","article-title":"HDAC3 improves intestinal function of mice by regulating cGAS-Sting pathway of intestinal glial cells","volume":"162","author":"Li","year":"2023","journal-title":"Mol. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"107158","DOI":"10.1016\/j.isci.2023.107158","article-title":"HDAC3 promotes macrophage pyroptosis via regulating histone deacetylation in acute lung injury","volume":"26","author":"Li","year":"2023","journal-title":"iScience"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","article-title":"Ferroptosis, a new form of cell death: Opportunities and challenges in cancer","volume":"12","author":"Mou","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: The role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.immuni.2024.03.019","article-title":"Ironing out the role of ferroptosis in immunity","volume":"57","author":"Bell","year":"2024","journal-title":"Immunity"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tips.2023.06.005","article-title":"Ferroptosis of immune cells in the tumor microenvironment","volume":"44","author":"Kim","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Lin, Z., Zou, S., and Wen, K. (2023). The crosstalk of CD8+ T cells and ferroptosis in cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1255443"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","article-title":"CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability","volume":"33","author":"Ma","year":"2021","journal-title":"Cell Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1084\/jem.20140857","article-title":"T cell lipid peroxidation induces ferroptosis and prevents immunity to infection","volume":"212","author":"Matsushita","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-022-05443-0","article-title":"Ferroptosis of tumour neutrophils causes immune suppression in cancer","volume":"612","author":"Kim","year":"2022","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"104286","DOI":"10.1016\/j.cellimm.2021.104286","article-title":"Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy","volume":"362","author":"Adeshakin","year":"2021","journal-title":"Cell. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1016\/j.celrep.2019.10.070","article-title":"B1 and Marginal Zone B Cells but Not Follicular B2 Cells Require Gpx4 to Prevent Lipid Peroxidation and Ferroptosis","volume":"29","author":"Muri","year":"2019","journal-title":"Cell Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13046-023-02629-w","article-title":"L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis","volume":"42","author":"Cui","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Yao, L., Hou, J., Wu, X., Lu, Y., Jin, Z., Yu, Z., Yu, B., Li, J., Yang, Z., and Li, C. (2023). Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation. Redox Biol., 67.","DOI":"10.1016\/j.redox.2023.102923"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.cmet.2021.03.023","article-title":"Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment","volume":"33","author":"Poznanski","year":"2021","journal-title":"Cell Metab."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e004458","DOI":"10.1136\/jitc-2021-004458","article-title":"Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress","volume":"10","author":"Renken","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","article-title":"Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity","volume":"13","author":"Wiernicki","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41419-021-04122-8","article-title":"Sestrin2 protects dendrite cells against ferroptosis induced by sepsis","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"33514","DOI":"10.1021\/acsomega.3c03319","article-title":"Sinensetin Attenuated Macrophagic NLRP3 Inflammasomes Formation via SIRT1-NRF2 Signaling","volume":"8","author":"Lin","year":"2023","journal-title":"ACS Omega"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"155135","DOI":"10.1016\/j.phymed.2023.155135","article-title":"Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2\/HO-1\/GPX4 axis","volume":"122","author":"Yang","year":"2024","journal-title":"Phytomedicine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e2118300119","DOI":"10.1073\/pnas.2118300119","article-title":"Epstein-Barr virus latency programs dynamically sensitize B cells to ferroptosis","volume":"119","author":"Burton","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s42255-023-00856-1","article-title":"Asparagine restriction enhances CD8+ T cell metabolic fitness and antitumoral functionality through an NRF2-dependent stress response","volume":"5","author":"Gnanaprakasam","year":"2023","journal-title":"Nat. Metab."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13075-019-1876-0","article-title":"Baicalein ameliorates pristane-induced lupus nephritis via activating Nrf2\/HO-1 in myeloid-derived suppressor cells","volume":"21","author":"Li","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Yang, J., Zhang, M., Zhang, X., Zhou, Y., Ma, T., Liang, J., and Zhang, J. (2024). Glioblastoma-derived exosomes promote lipid accumulation and induce ferroptosis in dendritic cells via the NRF2\/GPX4 pathway. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1439191"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e18160","DOI":"10.1016\/j.heliyon.2023.e18160","article-title":"RGFP966 exerts neuroprotective effect via HDAC3\/Nrf2 pathway after surgical brain injury in rats","volume":"9","author":"Gu","year":"2023","journal-title":"Heliyon"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1152\/ajpendo.00465.2017","article-title":"HDAC3 inhibition in diabetic mice may activate Nrf2 preventing diabetes-induced liver damage and FGF21 synthesis and secretion leading to aortic protection","volume":"315","author":"Zhang","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/15459683231183716","article-title":"Histone Deacetylase 3 Inhibition Ameliorates Microglia-Mediated Neuro-Inflammation Via the SIRT1\/Nrf2 Pathway After Traumatic Spinal Cord Injury","volume":"37","author":"Chen","year":"2023","journal-title":"Neurorehabilit. Neural Repair"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1080\/10408398.2018.1509201","article-title":"The success and the challenge of all-trans retinoic acid in the treatment of cancer","volume":"59","author":"Ni","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ccell.2024.02.004","article-title":"Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells","volume":"42","author":"Colucci","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature13158","article-title":"Maternal retinoids control type 3 innate lymphoid cells and set the offspring immunity","volume":"508","author":"Ferreira","year":"2014","journal-title":"Nature"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.intimp.2010.11.008","article-title":"FOXP3 and ROR\u03b3t: Transcriptional regulation of Treg and Th17","volume":"11","author":"Chen","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cellimm.2007.11.001","article-title":"Retinoic acid promotes mouse splenic B cell surface IgG expression and maturation stimulated by CD40 and IL-4","volume":"249","author":"Chen","year":"2007","journal-title":"Cell Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.imbio.2013.05.003","article-title":"Retinoic acid and \u03b1-galactosylceramide regulate the expression of costimulatory receptors and transcription factors responsible for B cell activation and differentiation","volume":"218","author":"Chen","year":"2013","journal-title":"Immunobiology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.4049\/jimmunol.0900324","article-title":"Peroxisome proliferator-activated receptor gamma ligands enhance human B cell antibody production and differentiation","volume":"183","author":"Baglole","year":"2009","journal-title":"J. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"dev199713","DOI":"10.1242\/dev.199713","article-title":"Development of follicular dendritic cells in lymph nodes depends on retinoic acid-mediated signaling","volume":"148","author":"Koning","year":"2021","journal-title":"Development"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.immuni.2010.07.003","article-title":"The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut","volume":"33","author":"Suzuki","year":"2010","journal-title":"Immunity"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.imlet.2022.02.005","article-title":"Isolation of CD35+ follicular dendritic cells and its role in the differentiation from B cells to IgA+GL7+ cells","volume":"243","author":"Yamane","year":"2022","journal-title":"Immunol. Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ijc.10966","article-title":"Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid","volume":"104","author":"Jinushi","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10875-006-9068-5","article-title":"Retinoic acid enhances the production of IL-10 while reducing the synthesis of IL-12 and TNF-alpha from LPS-stimulated monocytes\/macrophages","volume":"27","author":"Wang","year":"2007","journal-title":"J. Clin. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Ko, H.J., Hong, S.W., Verma, R., Jung, J., Lee, M., Kim, N., Kim, D., Surh, C.D., Kim, K.S., and Rudra, D. (2020). Dietary Glucose Consumption Promotes RALDH Activity in Small Intestinal CD103+CD11b+ Dendritic Cells. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01897"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/mi.2015.50","article-title":"Generation and transcriptional programming of intestinal dendritic cells: Essential role of retinoic acid","volume":"9","author":"Zeng","year":"2016","journal-title":"Mucosal Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41385-021-00445-z","article-title":"Antibody secreting cells are critically dependent on integrin \u03b14\u03b27\/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis","volume":"15","author":"Tyler","year":"2022","journal-title":"Mucosal Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Liao, J., Yu, X., Huang, Z., He, Q., Yang, J., Zhang, Y., Chen, J., Song, W., Luo, J., and Tao, Q. (2024). Chemokines and lymphocyte homing in Sj\u00f6gren\u2019s syndrome. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1345381"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.it.2016.12.006","article-title":"Retinoic Acid and Immune Homeostasis: A Balancing Act","volume":"38","author":"Erkelens","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1607-551X(10)70081-4","article-title":"Histone chaperone Jun dimerization protein 2 (JDP2): Role in cellular senescence and aging","volume":"26","author":"Huang","year":"2010","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1128\/MCB.22.13.4815-4826.2002","article-title":"JDP2, a repressor of AP-1, recruits a histone deacetylase 3 complex to inhibit the retinoic acid-induced differentiation of F9 cells","volume":"22","author":"Jin","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Pan, J., Jin, C., Murata, T., and Yokoyama, K.K. (2004). Histone modification activities of JDP2 associated with retinoic acid-induced differentiation of F9 cells. Nucleic Acids Symposium Series, Oxford University Press.","DOI":"10.1093\/nass\/48.1.189"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"G1138","DOI":"10.1152\/ajpgi.00411.2015","article-title":"The SCFA butyrate stimulates the epithelial production of retinoic acid via inhibition of epithelial HDAC","volume":"310","author":"Schilderink","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbrc.2010.07.127","article-title":"The Ski protein negatively regulates Siah2-mediated HDAC3 degradation","volume":"399","author":"Zhao","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbrc.2009.03.141","article-title":"The Ski protein can inhibit ligand induced RARalpha and HDAC3 degradation in the retinoic acid signaling pathway","volume":"383","author":"Zhao","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2017.08.004","article-title":"Interleukin-8 in cancer pathogenesis, treatment and follow-up","volume":"60","author":"Alfaro","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_141","first-page":"2508","article-title":"CXCL8\/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis","volume":"141","author":"Dunbar","year":"2023","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pros.24275","article-title":"IL-8 protects prostate cancer cells from GSK-3\u03b2-induced oxidative stress by activating the mTOR signaling pathway","volume":"82","author":"Sun","year":"2022","journal-title":"Prostate"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e000326","DOI":"10.1136\/jitc-2019-000326","article-title":"Simultaneous inhibition of CXCR1\/2, TGF-\u03b2, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity","volume":"8","author":"Horn","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","article-title":"CXCR2 inhibition enables NASH-HCC immunotherapy","volume":"71","author":"Leslie","year":"2022","journal-title":"Gut"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat. Med."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Han, Z.J., Li, Y.B., Yang, L.X., Cheng, H.J., Liu, X., and Chen, H. (2021). Roles of the CXCL8-CXCR1\/2 Axis in the Tumor Microenvironment and Immunotherapy. Molecules, 27.","DOI":"10.3390\/molecules27010137"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1038\/onc.2017.108","article-title":"A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis","volume":"36","author":"Xiang","year":"2017","journal-title":"Oncogene"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Li, E., Yang, X., Du, Y., Wang, G., Chan, D.W., Wu, D., Xu, P., Ni, P., Xu, D., and Hu, Y. (2021). CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.667177"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Li, M., van Esch, B., Henricks, P.A.J., Folkerts, G., and Garssen, J. (2018). The Anti-inflammatory Effects of Short Chain Fatty Acids on Lipopolysaccharide- or Tumor Necrosis Factor \u03b1-Stimulated Endothelial Cells via Activation of GPR41\/43 and Inhibition of HDACs. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00533"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"70798","DOI":"10.18632\/oncotarget.19990","article-title":"Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells","volume":"8","author":"Gatla","year":"2017","journal-title":"Oncotarget"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41575-021-00568-5","article-title":"Neutrophils as potential therapeutic targets in hepatocellular carcinoma","volume":"19","author":"Geh","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1128\/MCB.00706-15","article-title":"Histone Deacetylase 3 Is Required for Efficient T Cell Development","volume":"35","author":"Stengel","year":"2015","journal-title":"Mol. Cell. Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/cbin.10729","article-title":"Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells","volume":"41","author":"Cacan","year":"2017","journal-title":"Cell. Biol. Int."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI77088","article-title":"FOXP3+ regulatory T cell development and function require histone\/protein deacetylase 3","volume":"125","author":"Wang","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1016\/j.cell.2024.04.023","article-title":"Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor","volume":"187","author":"Zhang","year":"2024","journal-title":"Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"13067","DOI":"10.1021\/acs.jmedchem.4c01062","article-title":"Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating\/Degrading and Antitumor Immune Effects","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Serganova, I., Chakraborty, S., Yamshon, S., Isshiki, Y., Bucktrout, R., Melnick, A., B\u00e9guelin, W., and Zappasodi, R. (2021). Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.805195"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1093\/nar\/gkz816","article-title":"Histone deacetylase 3 controls a transcriptional network required for B cell maturation","volume":"47","author":"Stengel","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/2159-8290.CD-16-1285","article-title":"Targeting HDAC3 in CREBBP-Mutant Lymphomas Counterstrikes Unopposed Enhancer Deacetylation of B-cell Signaling and Immune Response Genes","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/0008-5472.CAN-23-3250","article-title":"HDAC Inhibition Increases CXCL12 Secretion to Recruit Natural Killer Cells in Peripheral T-cell Lymphoma","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e14749","DOI":"10.7554\/eLife.14749","article-title":"A Herpesviral induction of RAE-1 NKG2D ligand expression occurs through release of HDAC mediated repression","volume":"5","author":"Greene","year":"2016","journal-title":"eLife"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1038\/onc.2009.117","article-title":"HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: Potential implications for the immunosurveillance of cancer","volume":"28","author":"Folgueras","year":"2009","journal-title":"Oncogene"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Zhao, P., Sun, X., Li, H., Liu, Y., Cui, Y., Tian, L., and Cheng, Y. (2022). c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation. Cancers, 14.","DOI":"10.3390\/cancers14030457"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"G\u00e9nin, P., Lin, R., Hiscott, J., and Civas, A. (2012). Recruitment of histone deacetylase 3 to the interferon-A gene promoters attenuates interferon expression. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038336"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"16007","DOI":"10.1073\/pnas.0506516102","article-title":"Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter","volume":"102","author":"Dong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Vassiliou, E., and Farias-Pereira, R. (2023). Impact of Lipid Metabolism on Macrophage Polarization: Implications for Inflammation and Tumor Immunity. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512032"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.4049\/jimmunol.1201168","article-title":"SOCS3 deficiency promotes M1 macrophage polarization and inflammation","volume":"189","author":"Qin","year":"2012","journal-title":"J. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"108259","DOI":"10.1016\/j.intimp.2021.108259","article-title":"RGFP966 is protective against lipopolysaccharide-induced depressive-like behaviors in mice by inhibiting neuroinflammation and microglial activation","volume":"101","author":"Bian","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.7150\/ijms.94592","article-title":"Macrophagic HDAC3 inhibition ameliorates Dextran Sulfate Sodium induced inflammatory bowel disease through GBP5-NLRP3 pathway","volume":"21","author":"Che","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"102062","DOI":"10.1016\/j.tube.2021.102062","article-title":"HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection","volume":"127","author":"Campo","year":"2021","journal-title":"Tuberculosis"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"121574","DOI":"10.1016\/j.lfs.2023.121574","article-title":"Pharmacological blockade of HDAC3 accelerates diabetic wound healing by regulating macrophage activation","volume":"321","author":"Karnam","year":"2023","journal-title":"Life Sci."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s12094-023-03304-4","article-title":"Tumor metabolic crosstalk and immunotherapy","volume":"26","author":"Zhang","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3121\/cmr.4.3.218","article-title":"Gene therapy for cancer treatment: Past, present and future","volume":"4","author":"Cross","year":"2006","journal-title":"Clin. Med. Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: Cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.seminoncol.2016.10.005","article-title":"Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers","volume":"43","author":"Grigg","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1084\/jem.179.3.1005","article-title":"Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes","volume":"179","author":"Bakker","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1158\/1078-0432.CCR-18-0638","article-title":"Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival","volume":"24","author":"Antonarakis","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Hiltensperger, M., and Krackhardt, A.M. (2023). Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1121030"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2033528","DOI":"10.1080\/2162402X.2022.2033528","article-title":"Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure","volume":"11","author":"Wachsmann","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-22-0028","article-title":"Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors","volume":"29","author":"Berman","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e000848","DOI":"10.1136\/jitc-2020-000848","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: Boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"Heemskerk","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1038\/leu.2017.130","article-title":"Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response","volume":"31","author":"Long","year":"2017","journal-title":"Leukemia"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13148-018-0589-6","article-title":"HDAC is indispensable for IFN-\u03b3-induced B7-H1 expression in gastric cancer","volume":"10","author":"Deng","year":"2018","journal-title":"Clin. Epigenet."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1158\/2326-6066.CIR-22-0317","article-title":"HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells","volume":"11","author":"Li","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"114065","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/10717544.2021.1927246","article-title":"Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy","volume":"28","author":"Lu","year":"2021","journal-title":"Drug Deliv."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e163291","DOI":"10.1172\/JCI163291","article-title":"Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models","volume":"133","author":"Lu","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13046-020-1536-x","article-title":"Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1\/c-Jun\/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells","volume":"39","author":"Wang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1158\/0008-5472.CAN-23-3942","article-title":"The Circadian Clock Component RORA Increases Immunosurveillance in Melanoma by Inhibiting PD-L1 Expression","volume":"84","author":"Liu","year":"2024","journal-title":"Cancer Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1200\/JCO.22.01490","article-title":"Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis","volume":"41","author":"Wu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Stergiou, I.E., Palamaris, K., Levidou, G., Tzimou, M., Papadakos, S.P., Mandrakis, G., Masaoutis, C., Rontogianni, D., and Theocharis, S. (2024). PD-L1 Expression in Neoplastic and Immune Cells of Thymic Epithelial Tumors: Correlations with Disease Characteristics and HDAC Expression. Biomedicines, 12.","DOI":"10.3390\/biomedicines12040772"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Wei, X., Liu, J., Cheng, J., Cai, W., Xie, W., Wang, K., Lin, L., Hou, J., Cai, J., and Zhuo, H. (2024). Super-enhancer-driven ZFP36L1 promotes PD-L1 expression in infiltrative gastric cancer. eLife, 13.","DOI":"10.7554\/eLife.96445"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1084\/jem.20182192","article-title":"STING-mediated disruption of calcium homeostasis chronically activates ER stress and primes T cell death","volume":"216","author":"Wu","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.immuni.2020.06.009","article-title":"Interferon-Independent Activities of Mammalian STING Mediate Antiviral Response and Tumor Immune Evasion","volume":"53","author":"Wu","year":"2020","journal-title":"Immunity"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","article-title":"STING-induced regulatory B cells compromise NK function in cancer immunity","volume":"610","author":"Li","year":"2022","journal-title":"Nature"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Chauvin, S.D., Stinson, W.A., Platt, D.J., Poddar, S., and Miner, J.J. (2023). Regulation of cGAS and STING signaling during inflammation and infection. J. Biol. Chem., 299.","DOI":"10.1016\/j.jbc.2023.104866"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS-STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/bs.apcsb.2019.09.004","article-title":"Interplay between inflammation and cancer","volume":"119","author":"Khandia","year":"2020","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Gong, J., Deng, X., Shen, L., Wu, S., Fan, H., and Liu, L. (2024). Curcumin and nanodelivery systems: New directions for targeted therapy and diagnosis of breast cancer. Biomed. Pharmacother., 180.","DOI":"10.1016\/j.biopha.2024.117404"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1124\/jpet.123.001845","article-title":"Small Peptide-Based Nanodelivery Systems for Cancer Therapy and Diagnosis","volume":"390","author":"Singh","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/nnm.14.154","article-title":"Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells","volume":"10","author":"Krishnamurthy","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"H\u00fclsmann, J., Lindemann, H., Wegener, J., K\u00fchne, M., Godmann, M., Koschella, A., Coldewey, S.M., Heinze, T., and Heinzel, T. (2023). Dually Modified Cellulose as a Non-Viral Vector for the Delivery and Uptake of HDAC3 siRNA. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15122659"},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Lins-Austin, B., Patel, S., Mietzsch, M., Brooke, D., Bennett, A., Venkatakrishnan, B., Van Vliet, K., Smith, A.N., Long, J.R., and McKenna, R. (2020). Adeno-Associated Virus (AAV) Capsid Stability and Liposome Remodeling During Endo\/Lysosomal pH Trafficking. Viruses, 12.","DOI":"10.3390\/v12060668"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.2174\/0929867324666170404142840","article-title":"Peptide-Drug Conjugate: A Novel Drug Design Approach","volume":"24","author":"Ma","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"M\u00fcller, B.M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J., Winzer, K.J., Dietel, M., Weichert, W., and Denkert, C. (2013). Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-215"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2010.08301.x","article-title":"Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia","volume":"150","author":"Moreno","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2011.03.032","article-title":"Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology","volume":"155","author":"Milane","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"e30731","DOI":"10.1097\/MD.0000000000030731","article-title":"Sintilimab combined with chidamide in the treatment of extranodal nature killer\/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review","volume":"101","author":"Xu","year":"2022","journal-title":"Medicine"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s11596-023-2805-7","article-title":"Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed\/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center","volume":"43","author":"Kong","year":"2023","journal-title":"Curr. Med. Sci."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/cam4.2097","article-title":"Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells","volume":"8","author":"Zhang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"e001696","DOI":"10.1136\/jitc-2020-001696","article-title":"Frequent amplification of HDACgenes and efficacy of HDACinhibitor chidamide andPD-1 blockade combination in softtissue sarcoma","volume":"9","author":"Que","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.2024024487","article-title":"Epigenetic agents plusanti-PD 1 reprogram thetumor microenvironment andrestore antitumor efficacy in Hodgkin lymphoma","volume":"144","author":"Nie","year":"2024","journal-title":"Blood"},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Chen, C., Zhang, W., Zhou, D., and Zhang, Y. (2021). Sintilimab and Chidamide for Refractory Transformed Diffuse Large BCell Lymphoma: ACase Report and A Literature Review. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.757403"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Gatti-Mays, M.E., Gameiro, S.R., Ozawa, Y., Knudson, K.M., Hicks, K.C., Palena, C., Cordes, L.M., Steinnberg, S.M., Francis, D., and Karzai, F. (2021). Improving the Odds in Advanced Breast Cancer WithCombination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDACInhibitor in Advanced Stage Breast Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.581801"},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Caponigro, F., DiGennaro, E., Ionna, F., Longo, F., Aversa, C., Pavone, E., Maglione, M.G., Di Marzo, M., Muto, P., and Cavalcanti, E. (2016). Phase II clinical study of valproic acidplus cisplatin andcetuximab in recurrent and\/or metastatic squamous cell carcinoma of Head andNeck-V-CHANCE trial. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2957-y"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/1535-7163.MCT-17-0957","article-title":"Histone Deacetylase Inhibition Has Targeted Clinical Benefit inARID1A-Mutated Advanced Urothelial Carcinoma","volume":"18","author":"Gupta","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.seminoncol.2023.03.006","article-title":"Outcomes with panobinostat in heavily pretreated multiple myeloma patients","volume":"50","author":"Pan","year":"2023","journal-title":"Semin. Oncol."},{"key":"ref_225","first-page":"CD012974","article-title":"Neoadjuvant treatment for stage IIIand IV cutaneous melanoma","volume":"1","author":"Gorry","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_226","first-page":"4570","article-title":"Salvage camrelizumab for anintractable NK\/T celllymphoma patient withtwo instances of intestinal perforation: A case report and literature review","volume":"27","author":"Xia","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/1078-0432.CCR-19-0727","article-title":"Cooperative Immune-Mediated Mechanisms of theHDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy","volume":"26","author":"Hicks","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1007-e1107","DOI":"10.1093\/oncolo\/oyad221","article-title":"Phase I Study ofEntinostat, Atezolizumab, Carboplatin, and Etoposide inPreviously Untreated Extensive-Stage Small Cell LungCancer, ETCTN 10399","volume":"28","author":"Gentzler","year":"2023","journal-title":"Oncologist"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/2\/182\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:33:04Z","timestamp":1760027584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/2\/182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":228,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["vaccines13020182"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13020182","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}